Previous 10 | Next 10 |
Neurocrine Biosciences (NASDAQ: NBIX ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, after market close. The consensus EPS Estimate is $0.59 (+152.7% Y/Y) and the consensus Revenue Estimate is $226.29M (+63.5% Y/Y). Over the last 2 years, NBIX has beaten EPS esti...
SAN DIEGO , May 5, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday , May 12, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. ...
Neurocrine Biosciences (NASDAQ: NBIX) announced Monday that the Food and Drug Administration (FDA) has approved Ongentys (opicapone), a daily pill for Parkinson's disease. Ongentys is an add-on treatment for Parkinson's patients who are currently taking the main first-line treatment, levodo...
The FDA approves Neurocrine Biosciences' (NASDAQ: NBIX ) Ongentys (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "OFF" episodes (times when the medication stops working and symptoms recur). More news on:...
SAN DIEGO , April 27, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral ONGENTYS ® (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in p...
Check out my extensive thesis article into Xenon: here Xenon provides corporate update in light of COVID-19 Xenon Pharmaceuticals ( XENE ) is developing a formidable and focused pipeline of anti-epileptic drugs: Source: Xenon As detailed in a previous article of mine on X...
SAN DIEGO , April 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Wednesday, May 6, 2020 . Neurocrine will then host a conference call and webcast to discuss it...
Neurocrine Biosciences (NASDAQ: NBIX ) provides an update on its business operations during the COVID-19 pandemic. More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , April 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregiv...
As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...